/**/ RNS Number : 9734S IQ-AI Limited 09 November 2023   IQ-AI Ltd (“IQ-AI” or the “Company”) Director Dealing and Conversion of Convertible ​Loan Notes IQ-AI Ltd has received a conversion notice from Trevor Brown, the CEO of IQ-AI, converting £100,000 convertible loan notes and associated interest, issued on 29 May 2019, at a price of 1.5

/**/ RNS Number : 8043S IQ-AI Limited 08 November 2023   IQ-AI Ltd (“IQ-AI” or the “Company”) IQ-AI Applies for FDA Pediatric Rare Disease Designation November 8, 2023, Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI, OTCBB: IQAIF), is pleased to announce it has submitted a Pediatric Rare Disease (“PRD”)

/**/ RNS Number : 5247S IQ-AI Limited 06 November 2023   TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to

/**/ RNS Number : 5666Q IQ-AI Limited 18 October 2023   IQ-AI Ltd   (“IQ-AI” or the “Company”)   IB Neuro Reveals the Hidden Secrets of High-Grade Glioma’s Invasive Margins   October 18, 2023, Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), is pleased to announce the results of a

/**/ RNS Number : 0709Q IQ-AI Limited 13 October 2023   IQ-AI Limited (“IQ-AI” or the “Company”)   Imaging Biometrics LLC Letter to shareholders IQ-AI Limited (“IQAI”) (LSE: IQAI) a developer and manufacturer of medical image processing platforms, has today released a letter to shareholders on behalf of Michael Schmainda, CEO of IQ-AI’s wholly owned

/**/ RNS Number : 0526P IQ-AI Limited 09 October 2023   IQ-AI Ltd (“IQ-AI” or the “Company”) IQ-AI Announces Orphan Drug Designation Status FDA grants orphan status to Gallium Maltolate for treating ATRT Total Voting Rights   Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), today announces the U.S. Food

/**/ RNS Number : 5384O IQ-AI Limited 03 October 2023   TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to

/**/ RNS Number : 9599M IQ-AI Limited 19 September 2023   19 September 2023 IQ-AI Limited (“IQ-AI” or the “Company”)   IQ-AI shares cease trading on the OTCQB Venture Market in the United States   Further to the announcement of 1 September 2021, IQ-AI Limited (LSE: IQAI) has decided to cease trading on the OTCQB

/**/ RNS Number : 7871L IQ-AI Limited 08 September 2023   8 September 2023 IQ-AI Ltd (“IQ-AI” or the “Company”)   Reduced Gadolinium Approach Validated with IB Neuro on 1.5T MR Scanners   Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), is pleased to announce the results of a study

/**/ RNS Number : 8096J IQ-AI Limited 18 August 2023   18 August 2023   IQ-AI Ltd (“IQ-AI” or the “Company“) Update on Collaboration Agreement with Mayo Clinic Further to the RNS dated 8 February 2022, IQ-AI Ltd (LSE: IQAI, OTCQB: IQAIF) announces that the collaboration agreement signed with the Mayo Clinic for the development